Your search for Warfarin returned 48 results

Purpose: The aim of this review is to discuss possible interactions that may occur between warfarin and fruit products. Methods: A literature search was conducted using the search terms: “warfarin (Coumadin®) and fruit interactions, warfarin and fruit, warfarin and fruit juice, case reports and clinical trials”.

For patients with established cardiovascular disease and atrial fibrillation, warfarin treatment correlates with a lower risk of a composite of death, myocardial infarction (MI), and ischemic stroke, with no increased risk of bleeding.

For warfarin-treated patients, carbamazepine co-treatment is associated with subtherapeutic anticoagulative effect and increased warfarin dose requirements, according to a study published online in the Journal of Thrombosis and Haemostasis.

For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.

For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.

A case report in the Journal of Pharmacy Practice is the first published instance of a patient that required >30% reduction in weekly warfarin dose after smoking cessation.

Dabigatran is associated with higher risks of major bleeding and gastrointestinal bleeding compared with warfarin, but patients taking dabigatran also have a reduced risk of intracranial bleeding compared with those taking warfarin, according to new research.

For patients with nonvalvular atrial fibrillation (NVAF), left atrial appendage closure (LAAC) is associated with reduced rates of hemorrhagic stroke, cardiovascular/unexplained death, and nonprocedural bleeding vs. warfarin.

Taking warfarin at the same time as glipizide or glimepiride may increase the risk of hospitalization, according to a study published online December 7 in The BMJ.

Obese patients taking warfarin have a higher risk of experiencing a bleeding event compared to their normal-weight counterparts, a new study suggests.